Veracyte | VCYT - Selling And Administration Expenses


Veracyte reported $51.73M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Agenus USD 23.6M 448K Sep/2025
Agilent USD 428M 37M Sep/2025
Anika Therapeutics USD 12.91M 17.8M Mar/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Bruker USD 247.2M 4.7M Dec/2025
Exact Sciences USD 491.64M 35.94M Sep/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Illumina USD 283M 27M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Laboratory Of America USD 538.6M 13.8M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Myriad Genetics USD 129M 1.3M Sep/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Siemens EUR 3.61B 489M Dec/2025
Sonic Healthcare AUD 2.52B 2.46B Dec/2024
Thermo Fisher Scientific USD 1.98B 182M Dec/2025
Veracyte USD 51.73M 5.91M Sep/2025
Waters USD 240.01M 25.78M Dec/2025